Aliskiren – an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension

References

• AziziMMenardJBisseryAPharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1-receptor antagonist valsartan on the angiotensin II-renin feedback interruptionJ Am Soc Nephrol20041531263315579516
   PubMed Web of Science ®Google Scholar
• AziziMWebbRNussbergerJRenin inhibition with aliskiren: where are we now, and where are we going?J Hypertens2006242435616508564
   PubMed Web of Science ®Google Scholar
• BrunnerHRGavrasHLaraghJHHypertension in man. Exposure of the renin and sodium components using angiotensin II blockadeCirc Res197424Suppl II35I43
   Google Scholar
• CasasJPChuaWLoukogeorgakisSEffect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysisLancet200536620263316338452
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• DahlöfBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• de GasparoMCuminFNussbergerJPharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteersBr J Clin Pharmacol198927587962667598
   PubMed Web of Science ®Google Scholar
• DieterichHKempCVaidyanathanSAliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteersClin Pharmacol Ther20067911124
   Web of Science ®Google Scholar
• DieterleWCorynenSMannJEffect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjectsBr J Clin Pharmacol200458433615373937
   PubMed Web of Science ®Google Scholar
• DieterleWCorynenSVaidyanathanSPharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidineInt J Clin Pharmacol Ther2005435273516300168
   PubMed Web of Science ®Google Scholar
• FisherNDLHollenbergNKRenin inhibition: what are the therapeutic opportunities?J Am Soc Nephrol200516592915703270
   PubMed Web of Science ®Google Scholar
• FlatherMDYusufSKoberLLong-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative GroupLancet200035515758110821360
   PubMed Web of Science ®Google Scholar
• FukamizuASugimuraKTakimotoEChimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genesJ Biol Chem199326811617218505294
   PubMed Web of Science ®Google Scholar
• GantenDWagnerJZehKSpecies specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genesProc Natl Acad Sci USA1992897806101502199
   PubMed Web of Science ®Google Scholar
• GradmanAHSchmiederRELinsRLAliskiren, a novel, orally-effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an AT1-receptor blocker in hypertensive patientsCirculation20051111012815723979
   PubMed Web of Science ®Google Scholar
• GrossFLazarJOrthHInhibition of the renin-angiotensinogen reaction by pepstatinScience19711756564109853
   PubMed Web of Science ®Google Scholar
• HerronJMitchellJOhBThe novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawalJ Clin Hypertens20068Suppl AA93
   Google Scholar
• HollenbergNKFisherNDPriceDAPathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin systemHypertension199832387929740600
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMfor the VALUE trial groupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436320223115207952
   PubMed Web of Science ®Google Scholar
• KarioKPickeringTGUmedaYMorning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. A prospective studyCirculation20031071401612642361
   PubMed Web of Science ®Google Scholar
• KimSIwaoHMolecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseasesPharmacol Rev200052113410699153
   PubMed Web of Science ®Google Scholar
• KleinbloesemCHWeberCFahrnerEHemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjectsClin Pharmacol Ther199353585928491068
   PubMed Web of Science ®Google Scholar
• MenardJBogerRSMoyseDMDose-dependent effects of the renin inhibitor zankiren HCI after a single oral dose in mildly sodium-depleted normotensive subjectsCirculation19959133087805235
   PubMed Web of Science ®Google Scholar
• NguyenGDelarueFBurckléCSpecific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigenKidney Int199650189719038943472
   PubMed Web of Science ®Google Scholar
• NguyenGDelarueFBurckléCPivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to reninJ Clin Invest200210914172712045255
   PubMed Web of Science ®Google Scholar
• NussbergerJWuerznerGJensenCAngiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalaprilHypertension200239E1811799102
   PubMed Web of Science ®Google Scholar
• O’BrienEAliskiren: a renin inhibitor offering a new approach for the treatment of hypertensionExpert Opin Investig Drugs200615126977
   PubMed Web of Science ®Google Scholar
• O’BrienEBartonJNussbergerJAliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blockerHypertension20074927684
   Google Scholar
• PilzBShagdarsurenEWellnerMAliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic ratsHypertension2005465697616103264
   PubMed Web of Science ®Google Scholar
• PoolJLSchmiederREAziziMAliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartanAm J Hypertens200720112017198906
   PubMed Web of Science ®Google Scholar
• RongenGALendersJWMSmitsPClinical pharmacokinetics and efficacy of renin inhibitorsClin Pharmacokinet1995296147586899
   PubMed Web of Science ®Google Scholar
• RuggenentiPPernaAGherardiGRenoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuriaLancet19993543596410437863
   PubMed Web of Science ®Google Scholar
• SicaDGradmanALederballeOAliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52-weeks) treatment of hypertensionEur Heart J200627Abstract Suppl12116272213
   PubMedGoogle Scholar
• SkeggsLTKahnJRLentzKEPreparation, purification, and amino acid sequence of a polypeptide renin substrateJ Exp Med19571064395313463253
   PubMed Web of Science ®Google Scholar
• StaessenJALiYRichartTOral renin inhibitorsLancet200636814495617055947
   PubMed Web of Science ®Google Scholar
• StaessenJALiYThijsLWangJGBlood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trialsHypertens Res20052838540716156503
   PubMed Web of Science ®Google Scholar
• StantonATherapeutic potential of renin inhibition in the management of cardiovascular disordersAm J Cardiovasc Drugs200333899414728059
   PubMedGoogle Scholar
• StantonAJensenCNussbergerJBlood pressure lowering in essential hypertension with an oral renin inhibitor, aliskirenHypertension20034211374314597641
   PubMed Web of Science ®Google Scholar
• TurnbullFEffects of different blood-pressure-lowering regimens on major cardiovascular evets: results of prospectively-designed overviews of randomised trialsLancet200336215273514615107
   PubMed Web of Science ®Google Scholar
• VaidyanathanSValenciaJKempCLack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteersInt J Clin Pract20066013435617073832
   PubMed Web of Science ®Google Scholar
• VaidyanathanSJermanyJYTehCAliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjectsBr J Clin Pharmacol2007626690817118124
   PubMed Web of Science ®Google Scholar
• VaidyanathanSWarrenVYehCPharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairmentClin Pharmacol2007472192200
   Google Scholar
• VillamilAChrysantSCalhounDThe novel renin inhibitor aliskiren provides effective blood pressure control in patients with hypertension when used alone or in combination with hydrochlorothiazideJ Clin Hypertens20068Suppl AA100
   Google Scholar
• WangJGStaessenJAFranklinSSSystolic and diastolic blood pressure lowering as determinants of cardiovascular outcomeHypertension2005459071315837826
   PubMed Web of Science ®Google Scholar
• WatanabeTBarkerTABerkBCAngiotensin II and the endothelium: diverse signals and effectsHypertension200545163915630047
   PubMed Web of Science ®Google Scholar
• WeirMBushCZhangJAntihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysisEur Heart J200627Abstract Suppl299
   Google Scholar
• WoodJMMaibaumJRahuelJStructure-based design of aliskiren, a novel orally effective renin inhibitorBiochem Biophys Res Commun200330869870512927775
   PubMed Web of Science ®Google Scholar
• WoodJMSchnellCRCuminFAliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive ratsJ Hypertens2005234172615662231
   PubMed Web of Science ®Google Scholar
• ZhaoCVaidyanathanSYehCMAliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitusClin Pharmacokinet20064511253417048976
   PubMed Web of Science ®Google Scholar